Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437868 | 0.94 | PTGS2 (0.39) | IDO1PTGS2TP53TRPA1MAPT | |
| Nitrogen SCHEMBL27562848 | 0.88 | PTGS2 (0.36) | IDO1PTGS2TP53TRPA1MAPT | |
| SCHEMBL18494541 | 0.87 | IDO1 (0.41) | IDO1PTGS2MAPTHTTSMN1; SMN2 | |
| Methoxymethane SCHEMBL27562970 | 0.86 | PTGS2 (0.44) | IDO1PTGS2TP53TRPA1MAPT | |
| SCHEMBL12514812 | 0.84 | TACR1 (0.41) | IDO1PTGS2TP53TRPA1MAPT | |
| SCHEMBL3987382 | 0.82 | PTGS2 (0.40) | IDO1PTGS2TRPA1MAPTHTT | |
| SCHEMBL16958713 | 0.82 | PTGS2 (0.32) | IDO1PTGS2MAPTHTTSMN1; SMN2 | |
| SCHEMBL30345292 | 0.82 | IDO1 (0.37) | IDO1PTGS2TP53MAPTHTT | |
| SCHEMBL30426554 | 0.82 | PTGS2 (0.32) | IDO1PTGS2MAPTHTTSMN1; SMN2 | |
| SCHEMBL8567773 | 0.82 | IDO1 (0.37) | IDO1PTGS2TP53MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661813-A | Electron donor-acceptor polymer and preparation method and application thereof | 中山大学 | 2025-03-21 | — | — | CN | claimed |
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-119661813-A | Electron donor-acceptor polymer and preparation method and application thereof | 中山大学 | 2025-03-21 | — | — | CN | disclosed |
| CN-112679531-B | Boron-containing compound and organic electroluminescent device containing same | 北京鼎材科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2025021217-A1 | QUINOLINE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-01-30 | — | — | WO | disclosed |
| CN-118388390-A | Deuterated indolyl urea compound and medical application thereof | 重庆中国药科大学创新研究院 | 2024-07-26 | — | — | CN | disclosed |
| EP-4363416-A1 | MK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-3416956-B1 | METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-04-10 | — | — | EP | disclosed |
| CN-117777004-A | Deuterated indolyl urea compound and medical application thereof | 重庆中国药科大学创新研究院 | 2024-03-29 | — | — | CN | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1675814-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060014962-A1 | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20050215578-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1550661-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005037763-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| EP-1475374-A1 | THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | IDO1 205/4885PTGS2 156/4885TP53 4655/4885 |
| US-20050215578-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | IDO1 890/4885PTGS2 2536/4885TP53 4373/4885 |
| US-20050080111-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | IDO1 4266/4885PTGS2 2286/4885TP53 4759/4885 |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | PPARA, PPARG, PPARD | IDO1 4639/4885PTGS2 396/4885TP53 2351/4885 |
| US-20060014962-A1 | Thiadiazole compound and use thereof | CBR3, TH, CYP2E1 | IDO1 446/4885PTGS2 2075/4885TP53 4840/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | IDO1 911/4885PTGS2 131/4885TP53 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.